Literature DB >> 33553160

Nuclear Factor-κB Activating Protein Plays an Oncogenic Role in Neuroblastoma Tumorigenesis and Recurrence Through the Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling Pathway.

Jun Liu1, Mingyu Zhang1, Ying Kan1, Wei Wang1, Jie Liu1, Jianhua Gong2, Jigang Yang1.   

Abstract

Nuclear factor-κB activating protein (NKAP) is a conserved nuclear protein that acts as an oncogene in various cancers and is associated with a poor prognosis. This study aimed to investigate the role of NKAP in neuroblastoma (NB) progression and recurrence. We compared NKAP gene expression between 89 recurrence and 134 non-recurrence patients with NB by utilizing the ArrayExpress database. The relationship between NKAP expression and clinicopathological features was evaluated by correlation analysis. We knocked down NKAP expression in NB1 and SK-N-SH cells by small interfering RNA transfection to verify its role in tumor proliferation, apoptosis, and the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling pathway. NKAP gene expression in NB tissues was significantly overexpressed in the recurrence group compared with the non-recurrence group, and NKAP was enriched in the PI3K/AKT pathway. Correlation analysis revealed NKAP expression was correlated with chromosome 11q deletion in patients with NB. Knockdown of NKAP expression significantly inhibited the proliferation and promoted the apoptosis of NB1 and SK-N-SH cells. Moreover, we found that small interfering NKAP significantly reduced p-PI3K and p-AKT expression. NKAP knockdown played an oncogenic role in NB by inhibiting PI3K/AKT signaling pathway activations both in vitro and in vivo. Our research revealed that NKAP mediates NB cells by inhibited proliferation and promoted apoptosis through activating the PI3K/AKT signaling pathways, and the expression of NKAP may act as a novel biomarker for predicting recurrence and chromosome 11q deletion in patients with NB.
Copyright © 2021 Liu, Zhang, Kan, Wang, Liu, Gong and Yang.

Entities:  

Keywords:  neuroblastoma; nuclear factor-κB activating protein; phosphatidylinositol 3-kinase/protein kinase B signaling pathway; recurrence; tumorigenesis

Year:  2021        PMID: 33553160      PMCID: PMC7859273          DOI: 10.3389/fcell.2020.622793

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  36 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  NLGN3 promotes neuroblastoma cell proliferation and growth through activating PI3K/AKT pathway.

Authors:  Zuoqing Li; Wenzong Gao; Yingchun Fei; Pengfei Gao; Qigen Xie; Juntao Xie; Zhe Xu
Journal:  Eur J Pharmacol       Date:  2019-05-28       Impact factor: 4.432

3.  Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN.

Authors:  Wolfgang Hartmann; Boris Digon-Söntgerath; Arend Koch; Anke Waha; Elmar Endl; Indra Dani; Dorota Denkhaus; Cynthia G Goodyer; Niels Sörensen; Otmar D Wiestler; Torsten Pietsch
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

4.  NKAP plays an oncogenic function partly through AKT signaling pathway in hepatocellular carcinoma.

Authors:  T Song; J Y Liu; J J Yang
Journal:  Neoplasma       Date:  2019-07-12       Impact factor: 2.575

5.  MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Authors:  Steven G DuBois; Rajen Mody; Arlene Naranjo; Collin Van Ryn; Douglas Russ; Derek Oldridge; Susan Kreissman; David L Baker; Marguerite Parisi; Barry L Shulkin; Harrison Bai; Sharon J Diskin; Vandana Batra; John M Maris; Julie R Park; Katherine K Matthay; Gregory Yanik
Journal:  Pediatr Blood Cancer       Date:  2017-04-06       Impact factor: 3.167

Review 6.  Neuroblastoma.

Authors:  Titilope A Ishola; Dai H Chung
Journal:  Surg Oncol       Date:  2007-10-31       Impact factor: 3.279

7.  NKAP is a novel RS-related protein that interacts with RNA and RNA binding proteins.

Authors:  Bhagyashri D Burgute; Vivek S Peche; Anna-Lena Steckelberg; Gernot Glöckner; Berthold Gaßen; Niels H Gehring; Angelika A Noegel
Journal:  Nucleic Acids Res       Date:  2013-12-17       Impact factor: 16.971

8.  Increased plasma concentration of cell-free DNA precedes disease recurrence in children with high-risk neuroblastoma.

Authors:  Yan Su; Lijun Wang; Chiyi Jiang; Zhixia Yue; Hongjun Fan; Huimin Hong; Chao Duan; Mei Jin; Dawei Zhang; Lihua Qiu; Xianfeng Cheng; Zhong Xu; Xiaoli Ma
Journal:  BMC Cancer       Date:  2020-02-06       Impact factor: 4.430

9.  The transcriptional repressor NKAP is required for the development of iNKT cells.

Authors:  Puspa Thapa; Joy Das; Douglas McWilliams; Michael Shapiro; Rhianna Sundsbak; Molly Nelson-Holte; Sarah Tangen; Joshua Anderson; Stephen Desiderio; Scott Hiebert; Derek B Sant'angelo; Virginia Smith Shapiro
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 10.  CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.

Authors:  Lisa A King; Roeland Lameris; Tanja D de Gruijl; Hans J van der Vliet
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

View more
  2 in total

1.  IL-1β promotes hypoxic vascular endothelial cell proliferation through the miR-24-3p/NKAP/NF-κB axis.

Authors:  Jiangnan Huang; Yumei Li; Zhiyuan Jiang; Lingjun Wu; Yueying Liu; Siwen Ma; Lang Li; Hui Wang
Journal:  Biosci Rep       Date:  2022-01-28       Impact factor: 3.840

2.  Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out.

Authors:  Leticia Szadai; Erika Velasquez; Beáta Szeitz; Natália Pinto de Almeida; Gilberto Domont; Lazaro Hiram Betancourt; Jeovanis Gil; Matilda Marko-Varga; Henriett Oskolas; Ágnes Judit Jánosi; Maria Del Carmen Boyano-Adánez; Lajos Kemény; Bo Baldetorp; Johan Malm; Peter Horvatovich; A Marcell Szász; István Balázs Németh; György Marko-Varga
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.